{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T07:01:12Z","timestamp":1784962872190,"version":"3.55.0"},"reference-count":33,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T00:00:00Z","timestamp":1651449600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Thoracic Cancer"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>In patients with non\u2010small cell lung cancer (NSCLC) harboring driver alterations, the efficacy of immune checkpoint inhibitors (ICIs) remains uncertain. Our study aimed to examine the first\u2010line ICI efficacy in patients with NSCLC harboring <jats:italic>KRAS<\/jats:italic>, <jats:italic>MET<\/jats:italic>, <jats:italic>FGFR<\/jats:italic>, <jats:italic>RET<\/jats:italic>, <jats:italic>BRAF<\/jats:italic>, and <jats:italic>HER2<\/jats:italic> alterations in a real\u2010world setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This single\u2010center, retrospective cohort study included patients with advanced NSCLC harboring <jats:italic>KRAS<\/jats:italic>, <jats:italic>MET<\/jats:italic>, <jats:italic>FGFR<\/jats:italic>, <jats:italic>RET<\/jats:italic>, <jats:italic>BRAF<\/jats:italic>, <jats:italic>HER2<\/jats:italic> alterations or driver\u2010negative, and were treated with first\u2010line ICI therapy. Best overall response, progression\u2010free survival (PFS), and overall survival (OS) were evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Seventy\u2010eight patients with NSCLC were included (median age, 72\u2009years): 67% were men, 15% were never\u2010smokers, and 83% had adenocarcinoma. The driver alterations involved <jats:italic>KRAS<\/jats:italic> (<jats:italic>n<\/jats:italic>\u00a0=\u00a021), <jats:italic>MET<\/jats:italic> (<jats:italic>n<\/jats:italic>\u00a0=\u00a06), <jats:italic>FGFR<\/jats:italic> (<jats:italic>n<\/jats:italic>\u00a0=\u00a03), <jats:italic>RET<\/jats:italic> (<jats:italic>n<\/jats:italic>\u00a0=\u00a02), <jats:italic>BRAF<\/jats:italic> (<jats:italic>n<\/jats:italic>\u00a0=\u00a02), <jats:italic>HER2<\/jats:italic> (<jats:italic>n<\/jats:italic>\u00a0=\u00a01), and driver\u2010negative (<jats:italic>n<\/jats:italic>\u00a0=\u00a043). The partial responses for <jats:italic>KRAS<\/jats:italic>, <jats:italic>MET<\/jats:italic>, <jats:italic>FGFR<\/jats:italic>, <jats:italic>RET<\/jats:italic>, <jats:italic>BRAF<\/jats:italic>, <jats:italic>HER2<\/jats:italic>, and driver\u2010negative were 57%, 50%, 100%, 50%, 100%, 0%, and 47%, respectively. The median PFS (months) was 16.2 (95% confidence interval [CI]: 6.3\u2013 not reached [NR]) for <jats:italic>KRAS<\/jats:italic>, 2.8 (95% CI: 2.7\u2013NR) for <jats:italic>MET<\/jats:italic>, 11.7 (95% CI: 5.9\u2013NR) for other alterations (<jats:italic>FGFR<\/jats:italic>, <jats:italic>RET<\/jats:italic>, <jats:italic>BRAF<\/jats:italic>, and <jats:italic>HER2<\/jats:italic>), and 10.0 (95% CI: 3.7\u201314.3) for driver\u2010negative, respectively. The median OS (months) was 31.3 (95% CI: 9.0\u2013NR) for <jats:italic>KRAS<\/jats:italic>, not reached for <jats:italic>MET<\/jats:italic>, 23.5 (95% CI: 18.3\u2013NR) for other alterations, and 21.1 (95% CI: 15.2\u2013NR) for driver\u2010negative, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The benefit of the first\u2010line ICI was similar in advanced NSCLC regardless of the driver alterations, except for <jats:italic>MET<\/jats:italic> alterations.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1759-7714.14448","type":"journal-article","created":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T08:48:20Z","timestamp":1651481300000},"page":"1703-1711","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Efficacy of first\u2010line immune checkpoint inhibitors in patients with advanced <scp>NSCLC<\/scp> with <scp><i>KRAS<\/i><\/scp>, <scp><i>MET<\/i><\/scp>, <scp><i>FGFR<\/i><\/scp>, <scp><i>RET<\/i><\/scp>, <scp><i>BRAF<\/i><\/scp>, and <scp><i>HER2<\/i><\/scp> alterations"],"prefix":"10.1111","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8047-8730","authenticated-orcid":false,"given":"Yuji","family":"Uehara","sequence":"first","affiliation":[{"name":"Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital  Bunkyo\u2010ku Tokyo Japan"},{"name":"Department of Precision Cancer Medicine, Center for Innovative Cancer Treatment, Graduate School of Medical and Dental Sciences Tokyo Medical and Dental University  Bunkyo\u2010ku Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kageaki","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital  Bunkyo\u2010ku Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9980-4417","authenticated-orcid":false,"given":"Taiki","family":"Hakozaki","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital  Bunkyo\u2010ku Tokyo Japan"},{"name":"Department of Life Science and Medical Bioscience Waseda University  Shinjuku Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Yomota","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital  Bunkyo\u2010ku Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3849-5905","authenticated-orcid":false,"given":"Yukio","family":"Hosomi","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital  Bunkyo\u2010ku Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,5,2]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01113"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112431"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.05.041"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0645"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.03.035"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30144-X"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.10.007"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz453.001"},{"issue":"12","key":"e_1_2_7_10_1","first-page":"e1396403","article-title":"Impact of PD\u2010L1 expression, driver mutations and clinical characteristics on survival after anti\u2010PD\u20101\/PD\u2010L1 immunotherapy versus chemotherapy in non\u2010small\u2010cell lung cancer: a meta\u2010analysis of randomized trials","volume":"7","author":"Huang Q","year":"2018","journal-title":"Onco Targets Ther"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.01.011"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2021.100330"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.12.129"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy334"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz167"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.04.024"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.9059"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.9060"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002891"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.e21032"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.e21123"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2733"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002787"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0234-3"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.21873\/cgp.20160"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2019.08.61"},{"issue":"6","key":"e_1_2_7_27_1","first-page":"6525","article-title":"Characterization of distinct types of KRAS mutation and its impact on first\u2010line platinum\u2010based chemotherapy in Chinese patients with advanced non\u2010small cell lung cancer","volume":"14","author":"Jia Y","year":"2017","journal-title":"Oncol Lett"},{"issue":"5","key":"e_1_2_7_28_1","first-page":"1759","article-title":"KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples. Transl lung","volume":"9","author":"Loong HH\u2010F","year":"2020","journal-title":"Cancer Res"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2020.04.18"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13447"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2021.100261"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.1914"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-1236"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23010245"}],"container-title":["Thoracic Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.14448","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1759-7714.14448","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.14448","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T13:26:22Z","timestamp":1692883582000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1759-7714.14448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,2]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1111\/1759-7714.14448"],"URL":"https:\/\/doi.org\/10.1111\/1759-7714.14448","archive":["Portico"],"relation":{},"ISSN":["1759-7706","1759-7714"],"issn-type":[{"value":"1759-7706","type":"print"},{"value":"1759-7714","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,2]]},"assertion":[{"value":"2022-04-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}